WS Investor
29 Sep 2026, 20:47
Alnylam Launches AMVUTTRA Awareness Initiative to Highlight Earlier ATTR-CM Diagnosis
Alnylam Pharmaceuticals has launched a new U.S. educational initiative called “Play by Play” to raise awareness of transthyretin amyloid cardiomyopathy, or ATTR-CM, and encourage earlier diagnosis of the progressive heart disease.
The campaign features former professional athletes living with ATTR-CM, beginning with retired football player Pete Shaw, alongside caregivers and healthcare professionals. Alnylam said the initiative is designed to highlight symptoms that can be mistaken for aging or other cardiovascular conditions, including shortness of breath, fatigue, leg swelling and irregular heart rhythms.
The campaign also promotes AMVUTTRA, Alnylam’s RNAi therapy that silences transthyretin, or TTR, at the source of the disease. AMVUTTRA is administered by subcutaneous injection four times per year and is approved in the U.S. for adults with ATTR-CM as well as hereditary ATTR polyneuropathy.
In the Phase 3 HELIOS-B study, AMVUTTRA reduced the risk of all-cause mortality and recurrent cardiovascular events by 28.2% in the overall population and 32.8% in the monotherapy population through 36 months compared with placebo.
Alnylam estimates that more than 500,000 people worldwide live with transthyretin amyloidosis, with roughly 80% remaining undiagnosed.
The initiative supports Alnylam’s broader commercial strategy around AMVUTTRA by combining patient education, earlier disease recognition and treatment awareness as the company works to expand adoption in the ATTR-CM market.
Alnylam Pharmaceuticals has launched a new U.S. educational initiative called “Play by Play” to raise awareness of transthyretin amyloid cardiomyopathy, or ATTR-CM, and encourage earlier diagnosis of the progressive heart disease.
The campaign features former professional athletes living with ATTR-CM, beginning with retired football player Pete Shaw, alongside caregivers and healthcare professionals. Alnylam said the initiative is designed to highlight symptoms that can be mistaken for aging or other cardiovascular conditions, including shortness of breath, fatigue, leg swelling and irregular heart rhythms.
The campaign also promotes AMVUTTRA, Alnylam’s RNAi therapy that silences transthyretin, or TTR, at the source of the disease. AMVUTTRA is administered by subcutaneous injection four times per year and is approved in the U.S. for adults with ATTR-CM as well as hereditary ATTR polyneuropathy.
In the Phase 3 HELIOS-B study, AMVUTTRA reduced the risk of all-cause mortality and recurrent cardiovascular events by 28.2% in the overall population and 32.8% in the monotherapy population through 36 months compared with placebo.
Alnylam estimates that more than 500,000 people worldwide live with transthyretin amyloidosis, with roughly 80% remaining undiagnosed.
The initiative supports Alnylam’s broader commercial strategy around AMVUTTRA by combining patient education, earlier disease recognition and treatment awareness as the company works to expand adoption in the ATTR-CM market.
